Email Us
View Reports

Dawnrays Pharmaceutical Limited Company Profile - Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

  • ID : 7823910  |  
  • Published : Apr-2018  |  
  • Region : Global  |  
  • Pages : 36   |  
  • Publisher : Market Data Forecast

Dawnrays Pharmaceutical (Holdings) Limited (Dawnrays) is an investment holding company engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The group is a subsidiary of Fortune United Group Limited. It has operations in Hong Kong, the British Virgin Islands and China. The group operates its business through two reportable segments: Manufacture and Sale of Intermediates and Bulk Medicines and Manufacture and Sale of Finished Drugs. Under the manufacture and sale of intermediates and bulk medicines segment, Dawnrays includes chemical and pharmaceutical intermediates. The bulk medicines offered by the group include anhydrous sodium carbonate sterile, sparfloxacin lactate, cetirizine hydrochloride, amlodipine besylate, cefotaxime acid, ceftriaxone sodium crude, cefoperazone, cefixme, cefepime sterile and cefuroxime sodium sterile. In FY2016, the Manufacture and Sale of Intermediates and Bulk Medicines segment reported revenue of RMB$163.58million, which accounted for 19.8% of the company’s total revenue. Under the manufacture and sale of finished drugs segment, Dawnrays segment includes antibiotics finished drugs and non-antibiotics finished drugs. Dawnrays offers a series of products under powder for injection category such as cefoperazone sodium, cefoperazone sodium and sulbactam sodium, ceftriaxone sodium, cefotaxime sodium, cefradine, ceftazidime, and other antibacterial series products such as sparfloxacin lactate tablet and clindamycin hydrochloride capsule. The group's system specific medicines cover therapeutic areas for cardiovascular system, anti-allergic, digestive system, urinary system, anti-infective, antipyretic analgesic, endocrine system and traditional chinese medicine. In FY2016, the Manufacture and Sale of finished drugs segment reported revenue of RMB$ 660.76million, which accounted for 80.2% of the company’s total revenue. Geographically, Dawnrays classified its operations into two segments: Mainland China and Other countries. In FY2016, the company generated 87.82% of the total revenue from Mainland China and Other countries (12.17%). Dawnrays subsidiaries include the following: Dawnrays International Company Limited; Suzhou Dawnrays Pharmaceutical Co., Ltd.; Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd; Dawnrays Pharma (Hong Kong) Limited; Guangdong Dawnrays Pharmaceutical Co., Ltd.; and Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd.

Scope of the Report

-- About the Company - Historical Details, Current Ownership Structure and basic overview of Dawnrays Pharmaceutical Limited in terms of revenue, net income, and operating income.

-- Financials - Details about Dawnrays Pharmaceutical Limited listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.

-- Company SWOT Analysis - Outlines Dawnrays Pharmaceutical Limited’s strengths, weaknesses, and opportunities and threats facing the company.

-- Recent Developments - Showcases Dawnrays Pharmaceutical Limited’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

-- Strategic Evaluation - Provides an overview of Dawnrays Pharmaceutical Limited’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

-- What domain does Dawnrays Pharmaceutical Limited operate and what are key points about it?

-- What is the product / service portfolio of Dawnrays Pharmaceutical Limited?

-- How has Dawnrays Pharmaceutical Limited performed financially from the 2013?

-- How does Dawnrays Pharmaceutical Limited rank among its peers in terms of revenue and market share?

-- What are Dawnrays Pharmaceutical Limited strengths and weaknesses and what opportunities and threats does it face?

-- What are Dawnrays Pharmaceutical Limited’s main growth strategies and how successful has the company been at implementing them?

-- What is the in-house technical capability of Dawnrays Pharmaceutical Limited? Where does it procure / outsource it?

Reasons to buy

-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost

-- 12 hour delivery time fulfilling your urgent requests as per your requirement

-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics

1. About the Company

1.1 History and Basic Facts

1.2 Ownership Structure and Key Executives

1.3 Head Office

1.4 Other Locations & Subsidiaries

1.5 List of Competitors

1.6 Employee Count & Distribution

2. Financials

2.1 Company Type (Listed / Unlisted)

2.2 Annual Statements

2.3 Key Financial Highlights

2.4 Region-wise Breakdown

3. Product / Services

3.1 Overview

3.2 Description

4. SWOT Analysis

4.1 SWOT Overview

4.2 Strengths

4.3 Weaknesses

4.4 Opportunities

4.5 Threats

5. Recent Developments

5.1 Mergers & Acquisitions

5.2 Partnerships, Collaborations & Joint Ventures

5.3 New Product Launches

5.4 Business Expansion / Divestment

6. Strategic Evaluation

6.1 Corporate Strategy

6.2 Legal Issues

6.3 Analyst Outlook

7. Technology Landscape

7.1 Industry

-- 7.1.1 Industry Snapshot

-- 7.1.2 IT Spend

-- 7.1.3 Key Information Technology Trends

7.2 Company

-- 7.2.1 IT Overview

-- 7.2.2 Key IT Technologies

-- 7.2.3 Recent IT Initiatives

-- 7.2.4 IT Outsourcing Engagements

-- 7.2.5 Key IT Management

-- 7.2.6 CIO/CTO Profile

Appendix

-- Methodology

-- About Us

-- Contact Us

-- Disclaimer

Fig.1: Company Snapshot

Fig.2: Locations Listing on Map

Table.1: Ownership Structure

Table.2: List of Competitors

Table.3: Annual Statements

Table.4: Key Financial Highlights

Table.5: Region-wise Breakdown

Table.6: Product/Services Overview

Table.7: Mergers & Acquisitions

Table.8: Partnerships, Collaborations & Joint Ventures

Table.9: New Product Launches

Table.10: Business Expansion / Divestment

Table 11: IT Budgets

Table 12: Key IT Management (CIO / CTO)

Table 13: IT Deals undertaken in the past years

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?